I partner with life sciences and technology companies to accomplish their general legal objectives, as well as guide them through financing transactions and public company reporting and compliance.
+1 858 550 6034 sclayton@cooley.com
Sean Clayton's practice focuses on the representation of public and private growth companies in general corporate matters, as well as a wide range of transactions, including public offerings, venture capital financings and M&A.
Download full bio
Gossamer Bio – $317 Million IPO
ViaCyte: $80 Million Series D Financing
NantKwest – $238 Million IPO
Horizon Pharma to Acquire Hyperion Therapeutics for $1.1 Billion
Ionis Pharmaceuticals Completes Rule 144A Offering of $500 Million of Convertible Senior Notes
Horizon Pharma Acquires Vidara Therapeutics and Enters Five-Year $300 Million Term Loan Facility
Cooley Advises Underwriters on Vital Therapies Initial Public Offering
Horizon Pharma $660 Million Acquisition of Vidara Therapeutics
Capital Markets
Public Companies
Emerging Companies
Mergers & Acquisitions
Venture Capital
Family
Sports
Brewing
Don’t know how Cooley does it but they always pull out great attorneys to work with and you are certainly that. We really appreciate your knowledge, experience and counsel through this process.
Stanford Law SchoolJD, Order of the Coif, 2003
University of California, San DiegoBA, Political Science and Economicssumma cum laude, Phi Beta Kappa, 2000
California
Gossamer Bio – $317 Million IPO February 21, 2019
ASLAN Pharmaceuticals – $42 Million IPO June 8, 2018
Vital Therapies – $40 Million Follow-on Offering March 29, 2017
View all
+1 858 550 6034 office +1 858 550 6420 fax sclayton@cooley.com
4401 Eastgate MallSan Diego, CA 92121-1909